Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1936 1
1946 7
1947 13
1949 4
1950 11
1951 8
1952 4
1953 4
1954 4
1955 11
1956 17
1957 10
1958 11
1959 2
1962 1
1963 1
1964 2
1966 2
1967 2
1968 5
1969 6
1970 45
1971 9
1972 7
1973 5
1974 13
1975 54
1976 79
1977 56
1978 62
1979 59
1980 66
1981 69
1982 109
1983 132
1984 139
1985 110
1986 158
1987 198
1988 149
1989 167
1990 187
1991 211
1992 193
1993 260
1994 227
1995 186
1996 216
1997 251
1998 259
1999 272
2000 239
2001 284
2002 252
2003 283
2004 399
2005 383
2006 353
2007 372
2008 398
2009 371
2010 403
2011 413
2012 424
2013 586
2014 629
2015 615
2016 620
2017 656
2018 746
2019 782
2020 852
2021 998
2022 954
2023 850
2024 909
2025 1029
2026 562

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,475 results

Results by year

Filters applied: . Clear all
Quoted phrases not found in phrase index: "4,6,7-trichloro-2-dibenzofuranol", "steoroids"
Page 1
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer.
Clusan L, Ferrière F, Flouriot G, Pakdel F. Clusan L, et al. Int J Mol Sci. 2023 Apr 6;24(7):6834. doi: 10.3390/ijms24076834. Int J Mol Sci. 2023. PMID: 37047814 Free PMC article. Review.
Breast cancer is the most common cancer and the deadliest among women worldwide. Estrogen signaling is closely associated with hormone-dependent breast cancer (estrogen and progesterone receptor positive), which accounts for two-th …
Breast cancer is the most common cancer and the deadliest among women worldwide. Estrogen signaling is closely associat …
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.
Huppert LA, Gumusay O, Idossa D, Rugo HS. Huppert LA, et al. CA Cancer J Clin. 2023 Sep-Oct;73(5):480-515. doi: 10.3322/caac.21777. Epub 2023 Mar 20. CA Cancer J Clin. 2023. PMID: 36939293 Free article. Review.
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. ...Chemotherapy i …
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the pr …
Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
Saatci O, Huynh-Dam KT, Sahin O. Saatci O, et al. J Mol Med (Berl). 2021 Dec;99(12):1691-1710. doi: 10.1007/s00109-021-02136-5. Epub 2021 Oct 8. J Mol Med (Berl). 2021. PMID: 34623477 Free PMC article. Review.
Estrogen receptor-positive (ER +) breast cancer accounts for approximately 75% of all breast cancers. ...However, resistance to endocrine therapies represents a major challenge, limiting the success of ER + breast cancer treatment. ...
Estrogen receptor-positive (ER +) breast cancer accounts for approximately 75% of all breast cancers. ...However, resistance t …
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Rugo HS, et al. ESMO Open. 2025 Jan;10(1):104103. doi: 10.1016/j.esmoop.2024.104103. Epub 2025 Jan 3. ESMO Open. 2025. PMID: 39754979 Free PMC article.
BACKGROUND: Randomized controlled trials have shown inconsistent overall survival (OS) benefit among the three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as first-line (1L) treatment of patients with hormone receptor-positive (HR+)/human epidermal growt …
BACKGROUND: Randomized controlled trials have shown inconsistent overall survival (OS) benefit among the three cyclin-dependent kinase 4 …
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer.
Sahin TK, Rizzo A, Guven DC, Aksoy S. Sahin TK, et al. Cancer Treat Rev. 2025 Apr;135:102924. doi: 10.1016/j.ctrv.2025.102924. Epub 2025 Mar 20. Cancer Treat Rev. 2025. PMID: 40121890 Review.
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard first-line treatment for hormone receptor-positive (HR + ) and HER2-negative metastatic breast cancer (mBC). ...Endocrine thera …
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard first-li …
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS. Burstein HJ, et al. J Clin Oncol. 2021 Dec 10;39(35):3959-3977. doi: 10.1200/JCO.21.01392. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324367 Free PMC article.
PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. METHODS: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. ...RECOMMENDATION …
PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (M …
Hormone Resistance.
Yu J. Yu J. Adv Exp Med Biol. 2021;1187:391-401. doi: 10.1007/978-981-32-9620-6_20. Adv Exp Med Biol. 2021. PMID: 33983590
Hormone therapy is a major therapy for hormone receptor-positive breast cancer that improves survival. However, despite these hormone treatments, there are de novo or acquired resistance of breast cancer. Many studies revealed these resistance m …
Hormone therapy is a major therapy for hormone receptor-positive breast cancer that improves survival. However, despite …
Menstrual Cycle Phase Has No Influence on Performance-Determining Variables in Endurance-Trained Athletes: The FENDURA Project.
Taylor MY, Osborne JO, Topranin VM, Engseth TP, Solli GS, Valsdottir D, Andersson E, Øistuen GF, Flatby I, Welde B, Morseth B, Haugen T, Sandbakk Ø, Noordhof DA. Taylor MY, et al. Med Sci Sports Exerc. 2024 Sep 1;56(9):1595-1605. doi: 10.1249/MSS.0000000000003447. Epub 2024 Apr 11. Med Sci Sports Exerc. 2024. PMID: 38600646
The test battery consisted of 4-6 5-min submaximal stages with stepwise speed increases, a 30-s all-out double-poling ski ergometer test, and a maximal incremental treadmill running test. RESULTS: At a group level, there was no effect of MC phase or the serum conc …
The test battery consisted of 4-6 5-min submaximal stages with stepwise speed increases, a 30-s all-out double-poling ski er …
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. Mayer EL, et al. J Clin Oncol. 2024 Jun 10;42(17):2050-2060. doi: 10.1200/JCO.23.01940. Epub 2024 Mar 21. J Clin Oncol. 2024. PMID: 38513188 Clinical Trial.
PURPOSE: Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if pati …
PURPOSE: Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone re …
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.
Singareeka Raghavendra A, Damodaran S, Barcenas CH, Fuqua SA, Layman RM, Tripathy D. Singareeka Raghavendra A, et al. CA Cancer J Clin. 2026 Jan-Feb;76(1):e70055. doi: 10.3322/caac.70055. CA Cancer J Clin. 2026. PMID: 41524544 Free PMC article. Review.
The hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. ...Advances in targeted therapies, such as CDK4/6 (cyclin-dependent kinase 4 …
The hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer subtype accounts for …
17,475 results
You have reached the last available page of results. Please see the User Guide for more information.